Company intelligence / Profile preview

Biomics Biotechnologies

Nantong, Jiangsu, China

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Biomics Biotechnologies built a strong RNA interference (RNAi) platform and launched commercial skincare/depigmentation products. Its Hepatitis B therapeutic program, formerly partnered with Benitec Biopharma, was acquired by Benitec after promising in vitro preclinical data; Biomics retains a royalty interest and continues pre-clinical work on additional RNAi programs for AMD, bladder cancer, and more[1][5].

Therapeutic areas: OncologyInfectious DiseasesOphthalmologyDermatology
Modalities: Small interfering RNADouble stranded RNARNA therapyLiposome-based drug deliveryNanoparticle delivery (via partnerships, platforms)
Industry: Biotech

Partnerships

Benitec Biopharma (Hepatitis B RNAi program; partnership and IP licensing, later asset sale)

Beyond the preview

Go deeper on Biomics Biotechnologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biomics Biotechnologies.

Explore the full profile